CME Presentations

NORD Neuromuscular Congress


Presentations


Speakers

  • Ericka Greene, MD

    Ericka Greene, MD

    Ericka Greene, MD

    Sumner Family Chair in Neuromuscular Research

    Ericka Greene, MD, is the Sumner Family Chair in Neuromuscular Research, director of the Neuromuscular Clinic, and director of the Neurology Residency Program at Houston Methodist Hospital in Texas. Her clinical interests include a wide range of neuromuscular disorders, such as muscular dystrophy, myasthenia gravis, neuropathy, ALS, inflammatory myopathy, and mitochondrial and metabolic myopathy. Dr Greene’s translational research seeks to identify and develop effective therapies that positively alter the natural progression of these diseases. She has been a researcher in many clinical trials, author of over 50 peer-reviewed articles and book chapters, and the recipient of multiple teaching awards.
  • Amanda Peltier, MD, MS

    Amanda Peltier, MD, MS

    Amanda Peltier, MD, MS

    Associate Professor of Neurology and Medicine

    Amanda Peltier, MD, MS, is an associate professor of neurology and medicine at Vanderbilt University Medical Center in Nashville, Tennessee. Her expertise is in neuromuscular and autonomic disorders with a clinical research focus in identifying biomarkers for better clinical trial design. Dr Peltier sees patients in the Vanderbilt muscular dystrophy and neurology clinics with myasthenia gravis, Lambert-Eaton myasthenic syndrome, ALS, peripheral neuropathies, and autonomic disorders. She has published over 40 peer-reviewed publications. Dr Peltier received her medical degree from Ohio State University School of Medicine in Columbus and completed her neurology training and neuromuscular fellowship at the University of Michigan in Ann Arbor.
  • Terry Heiman-Patterson, MD

    Terry Heiman-Patterson, MD

    Terry Heiman-Patterson, MD

    Professor of Neurology

    Terry Heiman-Patterson, MD is professor of neurology at the Lewis Katz School of Medicine at Temple University in Philadelphia, Pennsylvania, director of both the Center for Neurodegenerative Diseases and the MDA/ALS Center of Hope, and for more than 30 years has been director of the Muscular Dystrophy Clinic at Good Shepherd Rehabilitation Center in Allentown. Dr Heiman-Patterson received her medical degree and completed a neurology residency at Albany Medical College in New York, and completed both clinical and research postdoctoral fellowships at the University of Pennsylvania in Philadelphia. She is board-certified in neurology, with subspecialty certification in neuromuscular diseases. Her research focuses on ALS, and includes both clinical and laboratory interests.
  • David Lieberman, MD, PhD

    David Lieberman, MD, PhD

    David Lieberman, MD, PhD

    Attending Child Neurologist

    David Lieberman, MD, PhD, is a child neurologist and clinical director of the Comprehensive Rett Syndrome Program at Boston Children’s Hospital in Massachusetts. He is involved in several clinical trials and other clinical research projects on Rett syndrome and has co-authored several papers in the field. At Boston Children’s Hospital, Dr Lieberman follows more than 200 patients with Rett syndrome and Rett-related disorders. He completed his medical degree and his PhD in neuroscience at Stanford University School of Medicine in California. Dr Lieberman continued his training at Johns Hopkins University School of Medicine in Baltimore, Maryland, completing an internship in pediatrics and a residency in pediatric neurology.
  • Julie A. Parsons, MD

    Julie A. Parsons, MD

    Julie A. Parsons, MD

    Professor of Clinical Pediatrics and Neurology

    Julie A. Parsons, MD, is a professor of clinical pediatrics and neurology at the University of Colorado School of Medicine in Aurora, the Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders, and co-director of the neuromuscular clinic at Children’s Hospital Colorado. Her clinical interests include neuromuscular diseases such as muscular dystrophies, spinal muscular atrophy (SMA), and myotonic dystrophies. She is an active participant and principal investigator for many clinical trials, and is a member of organizations that include the Child Neurology Society and the American Academy of Neurology. Dr Parsons earned her MD from the University of Colorado School of Medicine, followed by residencies in pediatrics and child neurology and a neuromuscular medicine fellowship.

CME Information

Parallel Universes: Traditional Treatments vs Emerging Disease-modifying Therapies for Neuromuscular Disorders


PIM Logo PQH Logo

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:

LEMS: Enhancing Diagnostic Accuracy and Access to Therapy to Improve Muscle Function
  • Describe the clinical symptoms of LEMS, the correlation with small cell lung cancer, and the importance of early recognition and testing to confirm a diagnosis
  • Explain how new channel blocker formulations may fill a therapeutic gap for people with LEMS
  • Adopt a multidisciplinary approach to LEMS management, engaging HCPs from multiple disciplines, including oncologists and neuro-muscular specialists
Pathophysiology and Targeted Treatments: Enhancing Outcomes in MG
  • Describe the correlation between an enhanced understanding of the pathophysiology of myasthenia gravis and emerging confirmatory diagnostic serologic tests
  • Describe the efficacy, safety, and place in therapy of current and emerging treatments for myasthenia gravis
  • Explain the importance of multidisciplinary care with neuromuscular specialists, hematologists, thoracic surgeons, pulmonologists, oncologists, physical and occupational therapists, primary and specialist care physicians
ALS: The Era of Disease Modifying Therapies
  • Identify patient characteristics and symptoms that suggest a diagnosis of ALS so appropriate testing can be performed to rule out mimicking conditions and confirm a diagnosis
  • Explain the therapeutic rationale of current and emerging treatments for the management of ALS
  • Describe the importance of coordinated specialized multidisciplinary ALS care and its impact on quality of life and extend survival
SMA: Early Detection to Enhance Access to Genetic Testing and Disease Modifying Therapies
  • Describe the link between genetic mutations, the onset of symptoms, and the importance of early recognition and diagnosis of SMA to prevent irreversible loss of nerve function and ensure early access to effective and potentially curative treatment
  • Differentiate current and emerging treatment options to produce functional SMN protein levels
  • Explain the importance of a multidisciplinary team approach, including gastroenterology, nutritionist, pulmonology, orthopedics, and physical-therapy members, to maximize quality of life in patients with SMA
Rett Syndrome: Early Recognition and Emerging agents to Reduce Disease Burden
  • Recognize the subtle signs and symptoms of Rett syndrome to confirm diagnosis early in the disease course
  • Appraise the therapeutic potential of agents currently being investigated for the treatment of patients with Rett syndrome
  • Describe the need for coordinated comprehensive care provided at a specialty clinic, including neurology, developmental pediatrics, gastroenterology, orthopedics, speech, and occupational- and physical-therapy specialists
Jointly provided by Postgraduate Institute for Medicine (PIM) and PlatformQ Health Education, LLC (PQHE) working in collaboration with the National Organization for Rare Disorders (NORD).

ACKNOWLEDGEMENT

This activity is supported by educational grants from Acadia Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc., Biogen, Catalyst Pharmaceuticals, and Mitsubishi Tanabe Pharma America, Inc.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

Thursday, March 25, 2021:
  • 1:00pm – 2:00pm ET: LEMS: Enhancing Diagnostic Accuracy and Access to Therapy to Improve Muscle Function
  • 2:00pm – 3:00pm ET: Pathophysiology and Targeted Treatments: Enhancing Outcomes in MG
  • 3:00pm – 4:00pm ET: ALS: The Era of Disease Modifying Therapies
Thursday, April 1, 2021:
  • 2:00pm – 3:00pm ET: SMA: Early Detection to Enhance Access to Genetic Testing and Disease Modifying Therapies
  • 3:00pm – 4:00pm ET: Rett Syndrome: Early Recognition and Emerging agents to Reduce Disease Burden

Enduring Material

The enduring material will be available from March 25, 2021 to April 1, 2022

TARGET AUDIENCE

This activity is intended for neurologists; primary care, internal medicine, and pediatric clinicians; psychiatrists; nurse practitioners; physician assistants; physical therapists; physiatrists; social workers; genetics counsellors; pharmacists; and other HCPs who recognize, diagnose and treat patients with neurologic diseases.

ESTIMATED TIME TO COMPLETE

This activity consists of 5 sessions which should take approximately 5 hours to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.NeuroSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Ericka P. Greene, MD
Associate Professor of Neurology
Vice Chair of Education
Stanley H. Appel Department of Neurology
Weill Cornell Medical College-Houston Methodist Hospital
Royalty: Speaker Bureau – Alexion, CLS Behring
Consulting Fees: Argenx Inc.
Amanda C. Peltier, MD, MS
Associate Professor of Neurology and Medicine
Vanderbilt University Medical Center
Consulting Fees: Akcea, Alnylam, CLS Behring
Terry D. Heiman-Patterson, MD
Professor of Neurology
Director, Neurodegenerative Disease Center
Director, MDA ALS Center of Hope
Temple University Lewis Katz School of Medicine
Consulting Fees: Biogen, Biohaven, Cytokinetics Evolution Medical Communication, Evidera, ITF Pharma, IQVIA, MTPA, Orphazyme, Samus
Other: HMA Hospitals, MJH Holdings, Sate of California Institute for Regenerative Med, WebMD
Julie A. Parsons, MD
Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders
Professor of Clinical Pediatrics and Neurology
University of Colorado School of Medicine
Children's Hospital Colorado
Consulting Fees: Biogen, Scholar Rock, Genentech Roche, Novartis
Contracted Research: Biogen, Scholar Rock, AveXis
David N. Lieberman, MD, PhD
Attending Child Neurologist
Assistant, Department of Neurology
Instructor of Neurology, Harvard Medical School
Boston Children’s Hospital
Department of Neurology
Consulting Fees: Taysha Gene Therapies
Contracted Research: Site PI for clinical trials supported by Acadia Pharmaceuticals, GW Research Limited, Anavex Life Sciences Corporation, and the Rett Syndrome Research Trust.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reported Financial Relationship
Carole Drexel
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 877-394-1306 or at Support@NeuroSeriesLive.com.